African-Americans and those living in high-poverty areas were more likely to present with an emergency diagnosis, indicating missed opportunities for screening. The study highlights the need to address these disparities to reduce mortality from colorectal cancer.
A study of 284 controls and 142 children with acute lymphoblastic leukemia found a higher risk associated with longer formula feeding and later solid food introduction. The risk increased by 16% for every month of formula feeding and 14% for each month the introduction of solid foods was delayed.
Patients with depression and short telomeres have a threefold increased risk for bladder cancer mortality, according to researchers. Lifestyle changes such as smoking cessation, weight loss, and increased physical activity may slow telomere shortening and improve survival.
A study found that consuming red meat increases the risk of bladder cancer, particularly in individuals with a genetic variation in the RAD52 gene that impairs DNA repair. The study suggests limiting red meat intake to reduce this risk.
A new noninvasive test measures DNA changes and fecal blood to detect precancerous lesions, showing high detection rates for cancers and precursors. The test achieved 98% sensitivity for all cancers and 83% for precursors with high-grade dysplasia.
Researchers have developed a noninvasive method to measure interstitial fluid pressure in tumors, which may help identify aggressive tumors. The technique uses dynamic contrast-enhanced MRI to evaluate the velocity of fluid flow from tumors and has been shown to correlate with tumor aggressiveness.
A new research model estimates that men with low-risk prostate cancer who choose active surveillance may live 6.4 years without treatment, while those who undergo immediate radical prostatectomy may gain an average of 1.8 months of additional life.
A phase II study found denosumab decreased giant cells and increased new bone formation in patients with giant-cell tumor of the bone, offering an alternative to radical surgery. The treatment reduced tumor burden by 90% or greater in all 20 patients, improving outcomes for young patients who previously required joint replacements.
Researchers found that high viral load and cancer-specific viral gene expression are key markers for identifying HPV-driven tumors. These findings suggest that HPV DNA positivity alone is a poor predictor of outcome in head and neck cancers.
Researchers found that PARP inhibitors are sensitive to HER2-positive breast cancer cells, even without a DNA repair defect. The study suggests that inhibition of NF-kB signaling may be a cause of this sensitivity, paving the way for further research and potential broadened clinical application.
A study published in Cancer Discovery reveals PARP1 and EZH2 as potential therapeutic targets for small cell lung cancer. The discovery could lead to the development of targeted treatments for this aggressive type of cancer, which currently has limited treatment options.
Researchers have identified molecular markers that can predict the progression of low-grade oral premalignant lesions to cancer. These markers, including loss of heterozygosity, help clinicians determine which patients are at high risk for progression and need closer follow-up.
The study found that the absence or downregulation of the LRP1B gene is associated with chemoresistance in high-grade serous ovarian cancer. Additionally, tumors that initially responded to chemotherapy but later became resistant evolved further than those that were resistant from the outset.
A phase III study published in Clinical Cancer Research found that denosumab reduced skeletal-related events by 31% compared to zoledronic acid, while also maintaining health-related quality of life. Treatment with denosumab also showed fewer acute reactions and adverse events.
Research finds that TRPM7 protein plays a critical role in breast cancer cell metastasis. High levels of TRPM7 expression are associated with poor patient outcomes and increased risk of distant metastases. The study suggests that targeting this protein could block metastasis, offering new therapeutic opportunities.
Researchers from Netherlands will investigate using DNA analysis to guide personalized cancer treatment, focusing on breast and colorectal tumors. The grant aims to improve patient outcomes by matching patients with the most effective treatments.
A study published in Cancer Research found that immune responses can be activated locally in the tumor microenvironment of melanoma skin metastases, contrary to previous thought. This discovery suggests that ectopic lymphoid structures may play a role in antimelanoma immune responses and has implications for treatment.
A preclinical study published in Cancer Discovery reports genetic validation for ongoing clinical trials testing IDO inhibitors in cancer patients. The findings suggest that IDO promotes tumorigenesis by enhancing vascularization and modifying the inflammatory environment, particularly in lung adenocarcinoma and metastatic disease.
The AACR-Kure It Grant will support innovative kidney cancer research, aiming to improve patient survival and quality of life. The grant recipient will receive $250,000 over two years and recognition at the AACR Annual Meeting.
A study published in Cancer Research found that increasing coffee consumption is inversely associated with the risk of developing basal cell carcinoma, the most common form of skin cancer. The study's results suggest that caffeine may be responsible for this decreased risk.
A high-fat/calorie diet has been shown to accelerate the development of pancreatic cancer in both human epidemiological studies and mouse models. In the latter, mice fed a diet rich in fat and calories developed obesity, insulin resistance, and inflammation, all conditions that can stimulate the growth of precancerous cells.
A novel chemotherapeutic agent, BAY 86-9766, has shown dramatic tumor shrinkage and prolonged survival in a genetically engineered mouse model of pancreatic ductal adenocarcinoma. The treatment was effective even in animals with advanced tumors and ascites, a common presentation in humans.
Researchers found that combining GDC-0449 with standard chemotherapy improved response rates and progression-free survival for patients with advanced pancreatic cancer. The treatment targets the desmoplastic stroma and pancreatic cancer stem cells, which contribute to disease resistance.
Researchers identified a genetic marker in the vitamin D receptor gene associated with improved overall survival rates among pancreatic cancer patients. The study's findings suggest that this genetic variation may play a role in the survival of patients treated for advanced pancreatic cancer.
A phase I study found the combination of erlotinib, bevacizumab, capecitabine, and radiotherapy to be safe and well-tolerated in patients with locally advanced pancreatic cancer. The regimen showed promising activity, with a low toxicity rate, and was associated with improved survival rates for some patients.
A new study has identified elevated levels of four neurotrophic factors in a mouse model of pancreatic cancer, which could be responsible for the development of pain in patients. These findings suggest that tumor-nerve interactions play a significant role in cancer progression and pain.
Researchers found that combining TH-302 with radiation reduced tumor growth in high and medium hypoxic xenografts, but not in low- or nonhypoxic implants. Tumor growth rates were also crucial in predicting treatment efficacy.
A new study proposes a highly accurate blood-based screen for pancreatic adenocarcinoma, which could lead to earlier detection and improved survival rates. Researchers identified 40 biomarkers with high sensitivity and specificity, offering hope for developing an effective panel.
A recent study has identified the RLIP76 protein as a key contributor to pancreatic cancer cell resistance to chemotherapy and radiation. Depleting levels of this protein was found to kill human pancreatic cancer cells in culture and shrink established tumors in mice, making it a potential new treatment target.
A population-based study has found that high levels of ultraviolet radiation at birth, sun-sensitive skin type, and a history of skin cancer decreased the risk of pancreatic cancer. Participants born in areas with high UV radiation had a 24% lower risk compared to those born in low UV areas.
Researchers have identified leukemia inhibitory factor (LIF) as a potential target to block the growth of cancer stem cells in pancreatic tumors. Blocking LIF activity has been shown to reduce the tumor's ability to regenerate and metastasize.
Researchers have discovered a novel mechanism for generating cancer-driving genes, bypassing chromosomal translocation. The SLC45A3-ELK4 fusion RNA promotes prostate cancer cell growth and disease progression in human samples.
Researchers found that metformin effectively eliminates cancer stem cells in pancreatic cancer, leading to tumor regression and long-term survival. Combining metformin with standard chemotherapy further eradicated both cancer stem cells and differentiated cancer cells.
Researchers have discovered JAK3 gene mutations in NK/T-cell lymphoma cells from 23 patients, suggesting the enzyme as a potential drug target. A Janus Kinase inhibitor already in phase III clinical trials for rheumatoid arthritis may also be effective against this cancer
A phase III clinical trial demonstrated sunitinib's effectiveness in treating resistant GIST tumors. The crossover design allowed patients to receive sunitinib after initial placebo treatment, protecting patient interests while maintaining rigorous proof of the drug's safety and efficacy.
A study published in Cancer Research found that weight loss of at least 5% reduced markers of inflammation in postmenopausal women. This reduction was observed even when exercise alone was not sufficient to decrease inflammation markers.
A preclinical study found that patients with KRAS gene mutations have a worse prognosis and do not respond well to targeted therapies. However, patients with KRAS-mutant tumors may respond well to treatment with antifolates, especially if the mutation is not amplified.
A phase II clinical trial showed encouraging survival in patients with stage 3B/4 non-small cell lung cancer (NSCLC) treated with belagenpumatucel-L. The median survival rate was 14.5 months, and the five-year survival rate was 20%. Patients with stable disease had a longer median survival of 44 months.
Researchers developed a multimarker molecular stool test that is highly sensitive to early-stage cancers and precancerous adenomas. The test was unaffected by variables such as age, sex, race, alcohol consumption, tobacco use, body mass, and medication use.
Researchers have found a promising combination of nab-paclitaxel and carboplatin to be effective in treating non-small cell lung cancer (NSCLC) patients who are ineligible for bevacizumab. The treatment resulted in an overall response rate of 41% and stable disease in 39% of patients.
Researchers found (S)-NNN to be a strong oral carcinogen, inducing oral cancer in rats. The chemical is present in smokeless tobacco products and has been linked to an increased risk of oral cavity cancers.
Scientists have discovered a new paradigm for immunotherapy against cancer by priming antibodies and T cells with cancer stem cells. The study found that purified cancer stem cells strengthened the potency of antibodies and T cells that selectively targeted cancer stem cells.
A new phase III study comparing the efficacy of Bacillus Calmette Guérin strains Tice and Connaught for non-muscle invasive bladder cancer treatment found that Connaught significantly reduced cancer recurrence rates, with a five-year recurrence-free survival rate of 75% compared to 46% for Tice. The study has the potential to shift the...
A phase II study found metformin reduced fasting glucose, insulin levels and body mass index in men with prostate cancer. The medication also appeared to slow the growth rate of prostate cancer in a proportion of men.
Galeterone, a small-molecule oral drug, demonstrated limited side effects and reduced prostate-specific antigen expression in patients with castration-resistant prostate cancer. The drug's triple mechanism of action showed promise in blocking the growth of prostate cancer cells.
Researchers identified pazopanib as a clinically meaningful treatment for refractory urothelial cancer. The study found that increases in interleukin-8 levels after treatment predicted a lack of tumor response, with 10% of patients experiencing long-term cure.
Researchers have discovered a new mechanism of prostate cancer cell metabolism by identifying the PFKFB4 gene, which is vital for tumor growth and antioxidant production. The study found that depletion of this gene in laboratory models inhibited tumor growth, suggesting potential targeted therapies.
Researchers discovered a DNA damage marker, telomeric allelic imbalance (tAI), that predicts sensitivity to platinum-based chemotherapy in patients with triple-negative breast cancer. The study found an inverse relationship between tAI and BRCA1 expression levels.
The Pancreatic Cancer Action Network and AACR have awarded $1.2 million in grants to two postdoctoral fellows, Stephanie K. Dougan and Oliver G. McDonald, to advance pancreatic cancer research through immunotherapy and epigenetic reprogramming studies.
A recent study published in Cancer Research suggests that dietary cadmium may be associated with an increased risk of breast cancer. Women who consumed higher amounts of whole grain and vegetables had a lower risk of breast cancer compared to those exposed through other foods.